Loading data for SABS — first visit, this takes a few seconds.

알림

SAB Biotherapeutics Inc. (SABS)

NasdaqCM: SABS · 실시간 가격 · USD

3.79

+0.02 (0.53%)

종가 기준: Aug 20, 2026, 8:00 PM

3.70

+0.00%

애프터마켓: 4:10 PM

0.53% (1D)

데이터 없음

매수호가	2.7
시가총액	336.65M
매출 (ttm)	n/a
순이익 (ttm)	-21.79M
베타	0.53
EPS (ttm)	0.24
P/E (ttm)	15.42
선행 P/E	-3.88
P/B (ttm)	1.44
P/S (ttm)	n/a
Earnings Date	Nov 12, 2026

매도호가	4.81
거래량	351,097
평균 거래량 (20일)	676,919
시가	3.75
전일 종가	3.77
일중 범위	3.67 - 3.82
52주 범위	1.85 - 5.15
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

SABS 소개

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founde...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 9, 2021

직원 수 86

상장 거래소 NasdaqCM

티커 SABS

웹사이트 https://www.sab.bio

전체 기업 정보

재무 실적

2025년 SAB Biotherapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 13.27M로, -138.92% 감소했습니다.

재무제표

어닝 서프라이즈

SAB Biotherapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.28 예상치 하회 0.00, 및 50.00% 전년 대비 성장.

다음 실적 발표

SAB Biotherapeutics Inc.의 실적 발표 예정일은 Nov 12, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · MarketBeat

SAB Biotherapeutics Q2 Earnings Call Highlights

SAB Biotherapeutics (NASDAQ:SABS) said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter ...

1주 전 · GuruFocus.com

SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...

Company on track to complete SAFEGUARD enrollment in Q4 2026 while expanding its pipeline with the PRIZE-HAPG study.

1개월 전 · Insider Monkey

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 that could triple. On July 7, SAB Biotherapeutics Inc. (NASDAQ:SABS) and Breakthrough T1D, a leading research and advocacy...

1개월 전 · Insider Monkey

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. Back-to-back bullish analyst calls are pointing to a wide gap be...

1개월 전 · Insider Monkey

Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)

SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 offering more than 50% upside. On June 24, Eliana Merle from Barclays initiated coverage of SAB Biotherapeutics Inc. (NASD...

2 페이지 중 1

SAB Biotherapeutics Inc. (SABS)